-
Sector Analysis
NewMethicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
Methicillin-Resistant Staphylococcus aureus (MRSA) Report Overview In the 7MM, there were 714,131 hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) in 2023. The hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) will register an AGR of more than 1% during 2023-2033. Methicillin-resistant Staphylococcus aureus (MRSA) is a virulent, antibiotic-resistant bacteria that is associated with considerable morbidity and mortality. MRSA can be categorized according to the setting in which the infection was acquired, as either healthcare-associated MRSA (HA-MRSA), which is acquired...
-
Product Insights
Likelihood of Approval Analysis for Pneumonia
Overview How likely is it that the drugs in Pneumonia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pneumonia Overview Pneumonia is a serious infection that causes inflammation and fluid in...
-
Product Insights
Likelihood of Approval Analysis for Bacterial Pneumonia
Overview How likely is it that the drugs in Bacterial Pneumonia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bacterial Pneumonia Overview Bacterial pneumonia is a lung infection caused by bacteria...
-
Product Insights
Likelihood of Approval Analysis for Meningitis
Overview How likely is it that the drugs in Meningitis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Meningitis Overview Meningitis is the inflammation of the meninges, protective membranes covering the...
-
Product Insights
Likelihood of Approval Analysis for Gram-Positive Bacterial Infections
Overview How likely is it that the drugs in Gram-Positive Bacterial Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gram-Positive Bacterial Infections Overview Gram-positive bacterial infections are caused by bacteria...
-
Product Insights
Likelihood of Approval Analysis for Gram-Negative Bacterial Infections
Overview How likely is it that the drugs in Gram-Negative Bacterial Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gram-Negative Bacterial Infections Overview Gram-negative bacterial infections are caused by a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalbavancin in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalbavancin in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalbavancin in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SER-155 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SER-155 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SER-155 in Graft Versus Host Disease (GVHD) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cefepime + Enmetazobactam) in Pyelonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cefepime + Enmetazobactam) in Pyelonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cefepime + Enmetazobactam) in Pyelonephritis Drug Details: Cefepime and Enmetazobactam (Exblifep)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Funobactam in Ventilator Associated Pneumonia (VAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Funobactam in Ventilator Associated Pneumonia (VAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Funobactam in Ventilator Associated Pneumonia (VAP) Drug Details: XNW-4107 is...